Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the various roles of steroids in vertebrate organ systems and notes several glucocorticoids that were among the Top 200 Drugs by sales in the 2010s, but it reports no new clinical findings.

This study found that five 0.1 mg dutasteride capsules are bioequivalent to one 0.5 mg dutasteride capsule in healthy adult males under fasting conditions, and both were well tolerated.

This study found that 5α-reductase inhibitors significantly reduced low-grade prostate cancer incidence in men but nearly doubled the incidence of high-grade prostate cancers.

This letter to the editor addresses corrections related to an earlier study on the effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer, but reports no new findings.

This cohort study using real-world data found no significant difference in the risk of developing prostate cancer between finasteride and dutasteride among patients with benign prostatic hyperplasia, despite previous suggestions that dutasteride might be more effective.

In this study, dutasteride 1 mg daily reduced heavy drinking days and drinks per week among treatment-seeking men, particularly benefiting those with high baseline drinking to cope motives.

Taking dutasteride every other day works as well as daily and better preserves sexual function.

This study found that in male mice, microglial changes due to a Parkinson's-like lesion were influenced by sex hormones, with dutasteride treatment preventing some effects.

This letter to the editor presents no new research results; it discusses a combination of dutasteride intralesional microinjections with oral minoxidil versus oral minoxidil alone for treating androgenetic alopecia in men.

This meta-analysis reported that the use of 5α-reductase inhibitors significantly increased the risk of postfinasteride syndrome-like adverse effects in men treated for benign prostatic hyperplasia or androgenetic alopecia.

This case report suggests that dutasteride may be a potential cause of cerebral venous thrombosis, as observed in a 25-year-old male presenting with headache and diplopia that improved after discontinuing the drug.

Tailored treatment is crucial for elderly men with BPH due to potential risks and benefits of medications.

This review discusses the clinical applications and adverse effects of 5-alpha reductase inhibitors for treating benign prostatic hyperplasia and androgenic alopecia, noting controversies around their implications for other diseases, without reporting new results.

Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.

This study found that from 2011 to 2015, a substantial portion of women in the Netherlands dispensed finasteride or dutasteride were not using adequate contraception, prompting calls for improved risk management.

Early surgery reduces seizure risk in drug-resistant epilepsy; testosterone to DHT conversion doesn't affect muscle anabolism; veterans with PTSD likely to have riskier opioid use; bevacizumab helps in hereditary bleeding disorder.

This review discusses the role of vitamins, micronutrients, and diets in prostate cancer prevention and reports no new clinical results, emphasizing a shift towards focusing on diet over supplements.

The authors concluded that dutasteride is effective and generally safe for managing benign prostatic hyperplasia and may reduce prostate cancer risk.

This study found that patients on dutasteride had $20.50 lower monthly medical costs compared to those on finasteride.

5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.

BMI should be considered in future research on dutasteride's effects on fertility.

Prescription and alternative therapies for hair loss will be compared for effectiveness.

In this study, researchers found a statistically significant increase in reports of suicidality and depression associated with finasteride use, especially in younger individuals, whereas dutasteride showed no significant signal for suicidality and a weaker signal for depression.

This study found that dutasteride improved maximum urinary flow rate more effectively than finasteride when used in combination therapy with tamsulosin for treating benign prostatic hyperplasia over six months.

This review concludes that oral dutasteride has the highest evidence level for stabilizing frontal fibrosing alopecia and should be used as a first-line treatment until more randomized controlled trials are conducted.

This case presentation reported worsening hyperglycemia in a diabetic male patient after starting finasteride, suggesting that 5-alpha reductase inhibitors may induce hyperglycemia through insulin resistance and liver disturbances in some individuals.

This cohort study found no overall increased risk of suicidal behaviors with finasteride versus dutasteride in men aged 50 and older, but suggested potential risk for those with a history of mood disorders.

This study explored a new dutasteride nanocarrier for alopecia therapy, concluding that ingredient concentration is key to achieving the optimal particle size, stability, and skin permeation for extended drug release.

This review discusses sex differences in Parkinson's disease and highlights that while men are more frequently affected, androgen-modulating treatments have not yet proven effective for PD, though 5α-reductase inhibitors show potential for further study.

This review assesses the potential of dutasteride as a promising treatment for ALS due to its reported neuroprotective, antioxidant, and anti-inflammatory effects, but emphasizes that clinical studies are needed for confirmation.